Molecular Imaging in Pancreatic Cancer--a Roadmap for Therapeutic Decisions

Overview

Journal Cancer Lett

Specialty Oncology

Date 2013 Aug 15

PMID 23941833

Citations 14

Authors

Gabriela Kramer-Marek

Jesse Gore

Murray Korc

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.

Citing Articles

Intra-Operative Tumour Detection and Staging in Pancreatic Cancer Surgery: An Integrative Review of Current Standards and Future Directions.

Kotb A, Hafeji Z, Jesry F, Lintern N, Pathak S, Smith A Cancers (Basel). 2024; 16(22).

PMID: 39594758 PMC: 11592681. DOI: 10.3390/cancers16223803.

Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities.

Farr K, Moses D, Haghighi K, Phillips P, Hillenbrand C, Chua B Cancers (Basel). 2022; 14(10).

PMID: 35626142 PMC: 9139708. DOI: 10.3390/cancers14102539.

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.

van Dam M, Vuijk F, Stibbe J, Houvast R, Luelmo S, Crobach S Cancers (Basel). 2021; 13(23).

PMID: 34885196 PMC: 8656821. DOI: 10.3390/cancers13236088.

LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma.

Acier A, Godard M, Gassiot F, Finetti P, Rubis M, Nowak J Commun Biol. 2021; 4(1):987.

PMID: 34413441 PMC: 8377056. DOI: 10.1038/s42003-021-02508-0.

Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling.

Knight J, Torres J, Goldin R, Mosley M, Dias G, Bravo L J Nucl Med. 2019; 61(7):1006-1013.

PMID: 31862800 PMC: 7383084. DOI: 10.2967/jnumed.119.234708.

References

Krautz C, Ruckert F, Saeger H, Pilarsky C, Grutzmann R . An update on molecular research of pancreatic adenocarcinoma. Anticancer Agents Med Chem. 2011; 11(5):411-7. DOI: 10.2174/187152011795677409. View

Xu Z, Vonlaufen A, Phillips P, Fiala-Beer E, Zhang X, Yang L . Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol. 2010; 177(5):2585-96. PMC: 2966814. DOI: 10.2353/ajpath.2010.090899. View

Wong H, Lemoine N . Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009; 6(7):412-22. PMC: 2882232. DOI: 10.1038/nrgastro.2009.89. View

Weissleder R, Mahmood U . Molecular imaging. Radiology. 2001; 219(2):316-33. DOI: 10.1148/radiology.219.2.r01ma19316. View

Michl P, Pauls S, Gress T . Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006; 20(2):227-51. DOI: 10.1016/j.bpg.2005.10.005. View

Fendrich V, Schneider R, Maitra A, Jacobsen I, Opfermann T, Bartsch D . Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia. 2011; 13(2):180-6. PMC: 3033596. DOI: 10.1593/neo.10956. View

DiMagno E, Buxton J, Regan P, Hattery R, Wilson D, Suarez J . Ultrasonic endoscope. Lancet. 1980; 1(8169):629-31. DOI: 10.1016/s0140-6736(80)91122-8. View

Saftoiu A, Vilmann P . Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. J Clin Ultrasound. 2008; 37(1):1-17. DOI: 10.1002/jcu.20534. View

Helmstaedter L, Riemann J . Pancreatic cancer--EUS and early diagnosis. Langenbecks Arch Surg. 2008; 393(6):923-7. DOI: 10.1007/s00423-007-0275-1. View

10.

Kindler H, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H . Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28(22):3617-22. PMC: 2917317. DOI: 10.1200/JCO.2010.28.1386. View

11.

Carriere C, Young A, Gunn J, Longnecker D, Korc M . Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS One. 2011; 6(11):e27725. PMC: 3225359. DOI: 10.1371/journal.pone.0027725. View

12.

Harewood G, Wiersema M . Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol. 2002; 97(6):1386-91. DOI: 10.1111/j.1572-0241.2002.05777.x. View

13.

Serrano O, Chaudhry M, Leach S . The role of PET scanning in pancreatic cancer. Adv Surg. 2010; 44:313-25. DOI: 10.1016/j.yasu.2010.05.007. View

14.

Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. PMC: 2998180. DOI: 10.1126/science.1171362. View

15.

Othman M, Wallace M . The role of endoscopic ultrasonography in the diagnosis and management of pancreatic cancer. Gastroenterol Clin North Am. 2012; 41(1):179-88. DOI: 10.1016/j.gtc.2011.12.014. View

16.

Nieto J, Grossbard M, Kozuch P . Metastatic pancreatic cancer 2008: is the glass less empty?. Oncologist. 2008; 13(5):562-76. DOI: 10.1634/theoncologist.2007-0181. View

17.

Duner S, Lopatko Lindman J, Ansari D, Gundewar C, Andersson R . Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology. 2011; 10(6):673-81. DOI: 10.1159/000320711. View

18.

Friess H, Langrehr J, Oettle H, Raedle J, Niedergethmann M, Dittrich C . A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer. 2006; 6:285. PMC: 1764757. DOI: 10.1186/1471-2407-6-285. View

19.

Yokoyama Y, Nagino M, Hiromatsu T, Yuasa N, Oda K, Arai T . Intense PET signal in the degenerative necrosis superimposed on chronic pancreatitis. Pancreas. 2005; 31(2):192-4. DOI: 10.1097/01.mpa.0000168226.36085.58. View

20.

Preis M, Korc M . Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther. 2010; 9(10):754-63. DOI: 10.4161/cbt.9.10.11534. View